Uveitis News and Research

RSS
Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.
TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Researchers find unique cell type that can protect against uveitis

Researchers find unique cell type that can protect against uveitis

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients

Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients

pSivida resubmits New Drug Application for ILUVIEN

pSivida resubmits New Drug Application for ILUVIEN

New weapon against secondary progressive MS

New weapon against secondary progressive MS

Simvastatin may slow progression of multiple sclerosis

Simvastatin may slow progression of multiple sclerosis

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida announces financial results for second quarter 2014

pSivida announces financial results for second quarter 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis